What is NephroSant?
Based in Brisbane, California, NephroSant is a fast-paced diagnostic startup leveraging the founding team's extensive clinical research expertise to advance global kidney health. The company is dedicated to developing innovative diagnostic solutions aimed at early detection and improved management of kidney-related conditions.
How much funding has NephroSant raised?
NephroSant has raised a total of $16M across 1 funding round:
Series A
$16M
Series A (2021): $16M with participation from DaVita Venture Group and DigitalDx Ventures
Key Investors in NephroSant
DaVita Venture Group
DaVita Venture Group is an investment arm focused on innovative solutions within the healthcare and kidney care sectors, aiming to drive advancements in patient outcomes and operational efficiencies.
DigitalDx Ventures
DIGITALDX focuses on investing in innovative solutions at the intersection of artificial intelligence and healthcare. The company aims to address significant market opportunities and impact through its portfolio of game-changing technologies. Its intended clients include healthcare providers and organizations looking to leverage AI for improved outcomes. The team comprises experts and advisors from various fields, enhancing its capability to drive advancements in healthcare.
What's next for NephroSant?
With its recent Series A financing, NephroSant is poised for significant growth and expansion. The substantial capital injection is expected to fuel further research and development, enhance its diagnostic platform, and potentially broaden its market reach. This strategic investment signals strong confidence from backers in NephroSant's mission to revolutionize kidney care through advanced diagnostics.
See full NephroSant company page
